Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT07267949
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Sponsor
- Acesion Pharma
- Registry
-
NCT07267949 -
2025-521377-14-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Bulgaria, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Serbia
- Registry status
- Recruiting
Technical summary
Registry record NCT07267949. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-22 (actual); primary completion 2027-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
- Acronym
- END-AF-1
- Condition
- Atrial Fibrillation (AF)
- Intervention (Drug)
- AP31969
- Intervention (Drug)
- Placebo
- Lead sponsor
- Acesion Pharma
Record details
- Record id
cardio:ct-nct07267949- Content hash
28745d99e5aacd26bfba7afc8cc3f759cfe4c09ce7925a54435bc16276273773